NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
PEPTONIC medical AB (“Peptonic” or “the Company”) completed a rights issue of units on Spotlight Stock Market in January 2023. Each warrant of series TO4 entitles to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO4 has been determined to 70 percent of the volume-weighted average price in the Company’s share on Spotlight Stock Market during the measurement period, which ran from and including April 2, 2024, up to and including April 15, 2024, however not higher than SEK 0.14 and not less than the quota value of the Company’s shares. During the measurement period, the volume-weighted average price in the Company’s share was approximately SEK 0.040, therefore, the exercise price for the warrants of series TO4 is SEK 0.028. The exercise period for warrants of series TO4 runs during the period from and including April 17, 2024, up to and including May 1, 2024.
If all the warrants of series TO4 are exercised, the Company will receive approximately SEK 5.5 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than May 1, 2024, or sell the warrants no later than April 26,2024. Please observe that certain nominees might close their application earlier than May 1, 2024.
Summarized terms for the warrants of series TO4:
Exercise period: April 17, 2024 – May 1, 2024.
Issue size: 196,370,600 warrants of series TO4, which entitles to subscription of 196,370,600 shares. If all warrants are exercised, the Company will receive approximately SEK 5.5 million before issuing costs.
Exercise price: SEK 0.028 per share.
Last day for trading warrants of series TO4: May 1, 2024.
Share capital and dilution: If all warrants are exercised the share capital will increase with SEK
4,909,265.00, from approximately SEK 38,371,139.91 to approximately SEK 43,280,404.91. If all warrants are exercised the number of shares in the Company will increase with 196,370,600 shares, from 1,534,845,596 shares to 1,731,216,196 shares. In the event that all warrants of series TO4 are exercised, the dilution amounts to approximately 11.34 percent of the number of existing shares in the Company.
Please be advised: The invested amount must be rounded up to two decimal places.
Please note that warrants that are not exercised on or before May 1, 2024, or sold on or before April 26, 2024, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
How warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.peptonicmedical.se, and on Mangold Fondkommission AB’s website, www.mangold.se.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of the warrants of series TO4.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
